Compare ConocoPhillips (COP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs State Street SPDR S&P Biotech ETF — how do they compare? ConocoPhillips trades at $134.15 (market cap $161.21B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: ConocoPhillips is far larger — about 15.9× State Street SPDR S&P Biotech ETF's market cap, and ConocoPhillips pays a 2.5% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| COP | XBI | |
|---|---|---|
Market Cap | $161.21B | $10.11B |
Volume | 6,058,403 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $141.22 | $169.55 |
52-Week Low | $85.66 | $104.99 |
Typical Hold Time | 79 Days | 38 Days |
Enterprise Value | $176.81B | — |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.52, up 3.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global. Valuation metrics appear reasonable with P/E at 17.75 and EV/EBITDA at 6.36, while profitability remains solid with 14.65% net income margin and 14.14% ROE.
Outlook remains positive with consensus price target of $154.75 representing 15% upside potential. Key risks include oil price volatility and geopolitical exposure in international operations. The company's strong cash flow generation and strategic LNG expansion provide growth catalysts, though investors should monitor execution on asset sales and energy market dynamics.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
